Celigo Advances studies in T Cell Therapy as a pediatric CHOP patient defeats her recurrent leukemia with immunotherapy

Emily Whitehead, cancer survivor, holding Nexcelom cell counting sheep.

Thanks to the lifesaving T cell therapy clinical trial at Children’s Hospital of Philadelphia, Emily Whitehead is now two years cancer free. Diagnosed with acute lymphoblastic leukemia (ALL) right after her 5^th birthday, doctors discovered that Emily’s leukemia was particularly resistant to chemotherapy, as are roughly 15% of the total number of ALL cases. After two recurrences of the disease, Emily’s parents enrolled her in a clinical trial for CTL019, an experimental therapeutic using a patient’s own reprogrammed T cells to eliminate the cancer cells. Now 9 years old, happy and healthy, Emily can finally lead a normal life. All evidence of the disease is gone, and Emily’s cancer-fighting T cells remain.

The Celigo is part of the growing tool box of technologies that are advancing T cell therapy research for patients with ALL and other cancers such as non-Hodgkin lymphoma, breast cancer, and other advanced stage cancers. To read more about Emily’s incredible story visit her website, Emily Whitehead :: My Journey Fighting Leukemia

To learn more about the Celigo Image Cytometer, you can reach out at info@nexcelom.com or call to speak with one of our specialists at 978-327-5340